Adjuvant Immunotherapy of Stage II Malignant Melanoma: Autologous Tumor Antigen Plus BCG

@inproceedings{Micksche1979AdjuvantIO,
  title={Adjuvant Immunotherapy of Stage II Malignant Melanoma: Autologous Tumor Antigen Plus BCG},
  author={Michael Micksche and Eva M. Kokoschka},
  year={1979}
}
In several clinical studies, nonspecific immunostimulation with BCG alone or combined with chemotherapy proved effective in prevention of recurrence and in increasing survival times of patients with stage II malignant melanoma (3, 10). The results of a randomized clinical trial comparing BCG therapy with no further therapy were in contrast to these findings. There was no benefit at all for patients receiving BCG in comparison to those treated by surgery only (H). Active specific immunotherapy… CONTINUE READING